ABC	Activated B-cell-like
aBCL	Aggressive B-cell lymphoma
Is noaLBCL	Aggressive large B-cell lymphoma
ASCT	Autologous stem cell transplantation
ASTCT	American Society for Transplantation and Cellular Therapy
Axi-cel	Axicabtagene ciloleucel
CAR T	Chimeric antigen receptor T cell
COO	Cell of Origin
CR	Complete response
CRS	Cytokine release syndrome
ctDNA	Circulating tumor deoxyribonucleic acid
DHL	Double-hit lymphoma
DLBCL	Diffuse large B-cell lymphoma
DOR	Duration of response
ECOG	Eastern Cooperative Oncology Group
EFS	Event-free survival
EHR	Electronic health record
FISH	Fluorescence in situ hybridization
GCB	Germinal center B-cell-like
GEP	Gene expression profile
HGBCL	High-grade B-cell lymphoma
HKSJ	Hartung–Knapp–Sidik–Jonkman
HR	Hazard ratio
ICANS	Immune effector cell-associated syndrome
IHC	Immunohistochemistry
Liso-cel	Lisocabtagene maraleucel
NHL	Non-Hodgkin’s lymphoma
OR	Odds ratio
OS	Overall survival
PFS	Progression-free survival
PI	Prediction interval
PMBCL	Primary mediastinal B-cell lymphoma
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
QUIPS	Quality In Prognosis Studies
R CHOP	Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
REML	Restricted maximum likelihood
R/R	Relapsed or refractory
THL	Triple-hit lymphoma
Tisa-cel	Tisagenlecleucel
TRM	Treatment-related mortality
vs	Versus
WT	Wild type